p27Kip1 - p(RhoB)lematic in lung cancer

Abstract

Lung cancer is the leading cause of cancer mortality worldwide, with adenocarcinomas of the non-small cell lung carcinoma (NSCLC) subtype accounting for the majority of cases. Therefore, an urgent need exists for a more detailed dissection of the molecular events driving NSCLC development and the identification of clinically relevant biomarkers. Even though originally identified as a tumour suppressor, recent studies associate the cytoplasmically (mis)localised CDK inhibitor p27^Kip1 (p27) with unfavourable responses to chemotherapy and poor outcomes in NSCLC, supporting the hypothesis that the protein can execute oncogenic activities. In a recent issue of The Journal of Pathology, Calvayrac and coworkers uncover a novel molecular mechanism that can explain this oncogenic role of p27. They demonstrate that cytoplasmic p27 binds and inhibits the small GTPase RhoB and thereby relieves a selection pressure for RhoB loss that is frequently observed in NSCLC. This is supported not only by studies with genetically modified mice, but also through identification of a cohort of human lung cancer patients with cytoplasmic p27 and continued RhoB expression, where this signature correlates with decreased survival. This not only establishes a potentially useful biomarker, but also provides yet another facet of the complex roles p27 undertakes in tumourigenesis. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Keywords: CDKN1B; NSCLC; RhoB; lung cancer; p27Kip1.

Figure 1

Schematic representation of the complex roles of p27^Kip1 in tumourigenesis including RhoB as a novel target of cytoplasmic p27. Tumour suppressive activities are shown in green and oncogenic activities in red. Indirect actions are indicated by dashed lines. For more details see text and references 1, 2, 3, 4. citron‐K, citron kinase; EMT, epithelial mesenchymal transition; miR, micro‐RNA; STMN, stathmin.